Monday, November 9, 2026

USD/EUR Is 2% Down In The Last 21 Sessions

USD/EUR Is 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.02% for the last 21 sessions. At 15:12 EST on Sunday, 23 July, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 1.285% up from its 52-week low and 14.301% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.14%, a negative 0.09%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.20% (last week), 0.35% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy trades with modest intraday losses below 140.00, lacks follow-through. According to FXStreet on Friday, 21 July, "This will be followed by the BoJ meeting on Thursday and Friday, which, in turn, should help investors to determine the near-term trajectory for the USD/JPY pair.", "A generally weaker tone around the equity markets, along with concerns over slowing growth in China, the worsening US-China relations and geopolitical risks, benefit the safe-haven Japanese Yen (JPY), which, in turn, exert pressure on the USD/JPY pair. "
  • Usd/jpy prints four-day winning streak above 140.00 despite upbeat Japan inflation, sluggish yields. According to FXStreet on Friday, 21 July, "Looking ahead, a light calendar may restrict immediate USD/JPY moves before the next week's monetary policy meetings of the Fed and the BoJ. ", "Although the 200-DMA puts a floor under the USD/JPY prices near 136.90, the Yen pair's immediate upside appears guarded by the 50-DMA hurdle of 140.60."
  • Usd/jpy rallies to near 142.00 as US dollar jumps and boj policy seems unchanged. According to FXStreet on Friday, 21 July, "The USD/JPY pair is swiftly marching towards the critical resistance of 142.00 in the European session. ", "The rally in USD/JPY is backed by expectations that policy divergence between the Fed and the Bank of Japan (BoJ) would escalate further as the Fed is expected to raise interest rates further while the BoJ will continue maintaining its decade-long ultra-dovish policy stance. "
  • Usd/jpy forecast: shows resilience against Japanese yen - 21 July 2023. According to DailyForex on Friday, 21 July, "If the USD/JPY pair manages to break above the ¥140.50 level, it could pave the way for further gains towards the ¥142.50 level, which has held historical importance.", "Traders are advised to remain cautious and prepare for potential volatility in the USD/JPY pair. "
  • Usd/jpy soars past 141.00 as boj’s would sticks to dovish stance, weakening the JPY. According to FXStreet on Friday, 21 July, "From a technical standpoint, the USD/JPY pair is set to continue upward biased, reclaiming during the session the Tenkan and Kijun-Sen level, with traders setting their eyes on the 142.00 mark. ", "To conclude, given the interest rate differentials, the USD/JPY uptrend might continue in the near term. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com